VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

CAdVax-ZEBOV/SEBOV
Vaccine Information
  • Vaccine Name: CAdVax-ZEBOV/SEBOV
  • Target Pathogen: Ebola virus
  • Target Disease: Ebola hemorrhagic fever
  • Vaccine Ontology ID: VO_0004641
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • Vector:
  • Preparation: A multivalent vaccine candidate (EBO7) that expresses the glycoproteins of Zaire ebolavirus (ZEBOV) and Sudan ebolavirus (SEBOV) in a single complex adenovirus-based vector (CAdVax) (Pratt et al., 2010).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Macaque Response

  • Vaccination Protocol: For the parenteral challenge studies, cynomolgus macaques were vaccinated intramuscularly (i.m.) on day zero with a 1:1 mixture of 1 × 10^10 PFU each of EBO7 and M8 (total 2 × 10^10 PFU). Control animals received an i.m. injection of 2 × 10^10 PFU of HC4. For the initial aerosol infection experiments, cynomolgus macaques were vaccinated by i.m. injection of 1 × 10^10 PFU of EBO7 or 1 × 10^10 PFU of HC4 (Pratt et al., 2010).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: For the aerosol infection group, twenty-eight days after vaccination, animals were anesthetized and exposed to a target dose of 1,000 PFU of either aerosolized ZEBOV or aerosolized SEBOV. For the parenteral challenge studies, six weeks after the boosting vaccinations, the macaques were anesthetized by i.m. injection of Telazol (2 to 6 mg/kg of body weight) and then inoculated i.m. with SEBOV or ZEBOV challenge stock (Pratt et al., 2010).
  • Efficacy: EBO7 vaccine provided protection against both Ebola viruses by either route of infection. Significantly, protection against SEBOV given as an aerosol challenge, which has not previously been shown, could be achieved with a boosting vaccination (Pratt et al., 2010).
References
Pratt et al., 2010: Pratt WD, Wang D, Nichols DK, Luo M, Woraratanadharm J, Dye JM, Holman DH, Dong JY. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clinical and vaccine immunology : CVI. 2010; 17(4); 572-581. [PubMed: 20181765].